Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 19/20 | 1.00 |
| ▸ | PDE1A | P54750 | 7/20 | 1.00 |
| ▸ | PDE1B | Q01064 | 7/20 | 1.00 |
| ▸ | PDE1C | Q14123 | 7/20 | 1.00 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.64 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.64 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.63 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.62 |
| ▸ | PDE6A | P16499 | 2/20 | 0.62 |
| ▸ | PDE2A | O00408 | 1/20 | 0.62 |
| ▸ | PDE6D | O43924 | 1/20 | 0.62 |
| ▸ | PDE9A | O76083 | 1/20 | 0.62 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.62 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.62 |
| ▸ | PDE6G | P18545 | 1/20 | 0.62 |
| ▸ | MAOA | P21397 | 1/20 | 0.62 |
| ▸ | PDE4A | P27815 | 1/20 | 0.62 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.62 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.62 |
| ▸ | PDE6B | P35913 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30493634 | 1.00 | PDE5A (1.00) | PDE5APDE1APDE1BPDE1CHDAC1 | |
| SCHEMBL6332323 | 0.93 | PDE5A (0.86) | PDE5APDE1APDE1BPDE1CHDAC1 | |
| SCHEMBL973661 | 0.93 | PDE5A (0.86) | PDE5APDE1APDE1BPDE1CHDAC1 | |
| SCHEMBL5901591 | 0.92 | PDE5A (0.85) | PDE5APDE1APDE1BPDE1CHDAC1 | |
| SCHEMBL5901813 | 0.92 | PDE5A (0.85) | PDE5APDE1APDE1BPDE1CHDAC1 | |
| SCHEMBL6332617 | 0.92 | PDE5A (0.85) | PDE5APDE1APDE1BPDE1CHDAC1 | |
| SCHEMBL14126907 | 0.88 | PDE5A (0.79) | PDE5APDE1APDE1BPDE1CHDAC1 | |
| SCHEMBL6852994 | 0.88 | PDE5A (0.79) | PDE5APDE1APDE1BPDE1CHDAC1 | |
| SCHEMBL972565 | 0.88 | PDE5A (0.79) | PDE5APDE1APDE1BPDE1CHDAC1 | |
| SCHEMBL15405142 | 0.87 | PDE5A (0.77) | PDE5APDE1APDE1BPDE1CHDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 105 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3083629-B1 | THE METHOD FOR MANUFACTURING OF VARDENAFIL AND ITS SALTS | ZAKL FARMACEUTYCZNE POLPHARMA SA (PL) | 2021-03-31 | — | — | EP | claimed |
| US-9845328-B2 | Method for manufacturing of vardenafil and its salts | ZAKLADY FARMACEUTYCZNE POLPHARMA S.A. (PL) | 2017-12-19 | — | — | US | claimed |
| US-20160311827-A1 | THE METHOD FOR MANUFACTURING OF VARDENAFIL AND ITS SALTS | ZAKLADY FARMACEUTYCZNE POLPHARMA S.A. (PL) | 2016-10-27 | — | — | US | claimed |
| WO-2013075680-A1 | A METHOD FOR THE PREPARATION AND ISOLATION OF SALTS OF VARDENAFIL WITH ACIDS | ZENTIVA, K.S. (CZ) | 2013-05-30 | — | — | WO | claimed |
| WO-2011079935-A2 | A PROCESS FOR THE PREPARATION AND ISOLATION OF VARDENAFIL AND SALTS THEREOF | ZAKLADY FARMACEUTYCZNE POLPHARMA SA (PL) | 2011-07-07 | — | — | WO | claimed |
| US-20070197535-A1 | POLYMORPHIC FORMS OF VARDENAFIL | DR. REDDY'S LABORATORIES, INC. | 2007-08-23 | — | — | US | claimed |
| WO-2006127368-A2 | METHODS FOR SYNTHESIZING IMIDAZOTRIAZINONES | LEXICON GENETICS INCORPORATED (US) | 2006-11-30 | — | — | WO | claimed |
| US-20060264624-A1 | Methods for synthesizing imidazotriazinones | LEXICON GENETICS INCORPORATED | 2006-11-23 | — | — | US | claimed |
| US-12576081-B2 | Methods and compositions for improving exercise performance, single ventricular performance, cardiac output and myocardial performance index (MPI) in single ventricular heart disease, using udenafil compositions | MEZZION PHARMA CO., LTD. (KR) | 2026-03-17 | — | — | US | disclosed |
| US-20250186448-A1 | FORMULATIONS OF UDENAFIL | MEZZION PHARMA CO LTD (KR) | 2025-06-12 | — | — | US | disclosed |
| US-20250064817-A1 | METHODS OF IMPROVING MYOCARDIAL PERFORMANCE IN FONTAN PATIENTS USING UDENAFIL COMPOSITIONS | MEZZION PHARMA CO., LTD. (KR) | 2025-02-27 | — | — | US | disclosed |
| EP-4452273-A1 | METHODS AND COMPOSITIONS FOR IMPROVING EXERCISE PERFORMANCE | Mezzion Pharma Co., Ltd. (US) | 2024-10-30 | — | — | EP | disclosed |
| US-20240285630-A1 | Methods and compositions for improving exercise performance | MEZZION PHARMA CO., LTD. (US) | 2024-08-29 | — | — | US | disclosed |
| CN-118436655-A | Methods of improving myocardial performance in Feng Tang Shu patients using Undenafil compositions | 美智恩制药公司 | 2024-08-06 | — | — | CN | disclosed |
| EP-1049695-B1 | 2-PHENYL SUBSTITUTED IMIDAZOTRIAZINONES AS PHOSPHODIESTERASE INHIBITORS | BAYER AG (DE) | 2002-02-13 | — | — | EP | disclosed |
| EP-1049695-B1 | 2-PHENYL SUBSTITUTED IMIDAZOTRIAZINONES AS PHOSPHODIESTERASE INHIBITORS | BAYER AG (DE) | 2002-02-13 | — | — | EP | disclosed |
| EP-1174431-A2 | 2-Phenyl-substituited Imidazotriazinones as Phoshodiesterase Inhibitors | Bayer Aktiengesellschaft (DE) | 2002-01-23 | — | — | EP | disclosed |
| WO-2001064677-A1 | NOVEL IMIDAZOTRIAZINONES AND THE USE THEREOF | BAYER AKTIENGESELLSCHAFT (DE) | 2001-09-07 | — | — | WO | disclosed |
| EP-1049695-A1 | 2-PHENYL SUBSTITUTED IMIDAZOTRIAZINONES AS PHOSPHODIESTERASE INHIBITORS | BAYER AG (DE) | 2000-11-08 | — | — | EP | disclosed |
| WO-1999024433-A1 | 2-PHENYL SUBSTITUTED IMIDAZOTRIAZINONES AS PHOSPHODIESTERASE INHIBITORS | BAYER AKTIENGESELLSCHAFT (DE) | 1999-05-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250064817-A1 | METHODS OF IMPROVING MYOCARDIAL PERFORMANCE IN FONTAN PATIENTS USING UDENAFIL COMPOSITIONS | TNNI3, TNNT2, FABP3 | PDE5A 7/4885PDE1A 198/4885PDE1B 178/4885 |
| US-20070197535-A1 | POLYMORPHIC FORMS OF VARDENAFIL | PDE5A, PDE3A, PDE4A | PDE5A 1/4885PDE1A 47/4885PDE1B 52/4885 |
| US-20250186448-A1 | FORMULATIONS OF UDENAFIL | SLC10A1, FGF1, SLC10A2 | PDE5A 37/4885PDE1A 705/4885PDE1B 806/4885 |
| US-20240285630-A1 | Methods and compositions for improving exercise performance | MAX, FABP3, TNNT2 | PDE5A 907/4885PDE1A 2532/4885PDE1B 2265/4885 |
| US-20160311827-A1 | THE METHOD FOR MANUFACTURING OF VARDENAFIL AND ITS SALTS | CYP3A5, KDM5A, KDM5C | PDE5A 6/4885PDE1A 565/4885PDE1B 463/4885 |
| US-12576081-B2 | Methods and compositions for improving exercise performance, single ventricular performance, cardiac output and myocardial performance index (MPI) in single ventricular heart disease, using udenafil compositions | TNNT2, TNNI3, NPPA | PDE5A 5/4885PDE1A 142/4885PDE1B 195/4885 |
| US-20060264624-A1 | Methods for synthesizing imidazotriazinones | PDE3A, PDE2A, PDE3B | PDE5A 4/4885PDE1A 37/4885PDE1B 56/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.